Literature DB >> 18080617

Chemotherapeutic Strategies for advanced breast cancer.

Susanne Briest1, Vered Stearns.   

Abstract

Disease-free and overall survival have improved significantly for women diagnosed with early-stage breast cancer. At the same time, systemic therapy has only slightly enhanced long-term outcomes in advanced breast cancer, a disease that remains largely incurable. Several single-agent and combination chemotherapy approaches are available to women with hormone-insensitive advanced disease that may improve overall survival and progression-free survival, minimize symptoms and complications related to the disease, and improve overall quality of life. In addition, new cytotoxic and targeted agents have been recently introduced into practice and have improved both survival outcomes and quality of life. In this review, we will provide an update on commonly used chemotherapy-based regimens for the treatment of metastatic breast cancer, with a focus on tailoring therapy to different subtypes of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 18080617

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

Review 1.  Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Authors:  Jiao Zhang; Yan-Hua Chen; Qun Lu
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Responding to a Community's Concern: A Comparison of Breast Cancer Characteristics and Initial Treatment in Three Selected North Carolina Counties.

Authors:  Anissa I Vines; William R Carpenter; Ronald C Chen; Michele W Cherry; Debra G Long; Keith D Amos; Paul A Godley
Journal:  N C Med J       Date:  2017 Nov-Dec

3.  Complete Response to Single-agent Palbociclib in Metastatic Breast Cancer: A Case Report.

Authors:  Sri Lakshmi Hyndavi Yeruva; Mehrbod Som Javadi; Vered Stearns
Journal:  Clin Breast Cancer       Date:  2017-12-21       Impact factor: 3.225

4.  Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.

Authors:  Karol M Pawłowski; Joanna Mucha; Kinga Majchrzak; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-06-17       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.